NextGenNK
NextGenNK is a Competence Center for the development of next generation NK cell-based cancer immunotherapies. The Center is coordinated by Karolinska Institutet and collaborates with the Karolinska University Hospital and prominent national and international industrial partners. The Center was launched in 2020, and is jointly funded by Vinnova, KI, and the Industrial partners.
News
Upcoming events
ATMP World Tour 2022
ATMP World Tour 2022
Join ATMP Sweden in a virtual trip around the world to highlight 'world leading' activities in ATMP. Registrations have opened!
XNK Therapeutics raises SEK 132 million to accelerate growth
XNK Therapeutics raises SEK 132 million to accelerate growth
XNK Therapeutics AB has secured a private placement of SEK 132 million, to existing and new investors, led by Flerie Invest AB.
Selected Publications
Autologous NK cells as consolidation therapy following stem cell transplantation in multiple myeloma
Nahi et al. Cell Rep Med. 2022
NK cells integrate signals over large areas when building immune synapses but require local stimuli for degranulation
Verron et al. Sci Immunol. 2021
The transcription factor Bcl11b promotes both canonical and adaptive NK cell differentiation
Holmes et al. Sci Immunol. 2021